Terazosin in the treatment of premature ejaculation: A short-term follow-up

Basit Öğe Kaydı
dc.contributor.authorBaşar M. Murad
dc.contributor.authorYılmaz Erdal
dc.contributor.authorFerhat Mehmet
dc.contributor.authorBaşar Halil
dc.contributor.authorBatislam Ertan
dc.date.accessioned2020-06-25T15:13:33Z
dc.date.available2020-06-25T15:13:33Z
dc.date.issued2005
dc.departmentKırıkkale Üniversitesi
dc.description.abstractAim: The aim of the present study was to evaluate the efficacy of terazosine in patients with premature ejaculation and lower urinary tract symptoms (LUTS), after excluding other sexual disorders and chronic prostatitis. Methods: A total of 90 patients with premature ejaculation and LUTS were enrolled to the study after excluding sexual disorders, prostatitis and benign prostatic hyperplasia. The patients were divided into two groups. Sixty patients in group 1 were treated with terazosine 5 mg daily for a month. Patients were followed monthly and questioned for their ejaculation problem. The results were classified as cure, improvement and ineffective. If patients showed improvement and ineffectiveness, the treatment was continued with 10 mg daily for the following month. Group 2 was included 30 patients, and placebo was applied for a month. At the end of this period, in patients who did not show any improvement, terazosine 10 mg was started. Results: In the treatment group, at the 1st month follow-up, 21 patients (35%) were cured, 20 (33.3%) showed improvement. In 19 (31.7%) patients, the treatment was ineffective. In group 2, 9 (30%) patients showed improvement and the rest had no-changes after one-month follow up. There was statistically significant difference between two groups (Pearson ? 2 test=0.000). Later, terazosine 10 mg was given to the patients in group 2 and to the patients who showed improvement or unsuccessful result with terazosine 5 mg. With terazosine 10 mg, 10 (14.5%) patients were cured, 29 (42.2%) patients were improved. Finally, terazosine treatment in patients with premature ejaculation was found to be effective in 60 patients (66.7%). Conclusion: Alpha blockers seem to be physiological medical agents in the treatment of premature ejaculation since ejaculation is under sympathetic control. Moreover, these agents are effective in lower urinary tract and they should be used in patients with premature ejaculation and lower urinary tract symptoms. © Springer 2005.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1007/s11255-005-3616-4
dc.identifier.endpage777en_US
dc.identifier.issn03011623
dc.identifier.issue4en_US
dc.identifier.pmid16362597
dc.identifier.scopus2-s2.0-31144467060
dc.identifier.scopusqualityQ2
dc.identifier.startpage773en_US
dc.identifier.urihttps://doi.org/10.1007/s11255-005-3616-4
dc.identifier.urihttps://hdl.handle.net/20.500.12587/1846
dc.identifier.volume37en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Netherlandsen_US
dc.relation.ispartofInternational Urology and Nephrology
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlpha blockersen_US
dc.subjectIIEFen_US
dc.subjectIPSSen_US
dc.subjectLowerurinary tract symptomsen_US
dc.subjectPrematureejaculationen_US
dc.subjectTerazosineen_US
dc.titleTerazosin in the treatment of premature ejaculation: A short-term follow-upen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Terazosin in the treatment of premature ejaculation A short-term follow-u.pdf
Boyut:
171.87 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu